Stockreport

Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeti...

Intellia Therapeutics, Inc.  (NTLA) 
Last intellia therapeutics, inc. earnings: 2/27 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.intelliatx.com/investor-overview
PDF CAMBRIDGE, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing [Read more]